Elucidation of the Intestinal Absorption Mechanism of Celastrol Using the Caco-2 Cell Transwell Model

Abstract

Celastrol, a triterpenoid isolated from stem (caulis) of Celastrus orbiculatus Thunb. (Celastraceae), has been known to have various pharmacological effects, including anti-inflammatory, anticancer, and antioxidant activities. However, the mechanism of the intestinal absorption of celastrol is unknown. The aim of this study was to investigate the intestinal absorption of celastrol using the Caco-2 cell transwell model. First, the bidirectional transport of celastrol in Caco-2 cell monolayers was observed. Then, the effects of time, concentration, temperature, paracellular pathway, and efflux transport inhibition on the transport of celastrol across the Caco-2 cell monolayers were investigated. The P-glycoprotein inhibitor verapamil and cyclosporin A, the multidrug resistance protein 2 inhibitor MK571, and the breast cancer resistance protein inhibitor reserpine were used. Additionally, the effects of celastrol on the activity of P-glycoprotein were evaluated using the rhodamine 123 uptake assay. In this study, we found that the intestinal transport of celastrol was a time- and concentration-dependent active transport. The paracellular pathway was not involved in the transport of celastrol, and the efflux of celastrol was energy dependent. The results indicated that celastrol is a substrate of P-glycoprotein but not multidrug resistance protein 2 or the breast cancer resistance protein. In addition, celastrol could not affect the uptake of rhodamine 123 in Caco-2 cells, which indicated that celastrol could not inhibit or induce the activity of P-glycoprotein.

Key words

Celastrus orbiculatus Thunb. - BCRP - Caco-2 cell - celastrol - MRP2 - P-gp

^* The first three authors contributed equally to this work.

• References

• 1 Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese “Thunder of God Vine,” is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006; 66: 4758-4765
• 2 Dai Y, Desano J, Tang W, Meng X, Meng Y, Burstein E, Lawrence TS, Xu L. Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One 2010; 5: e14153
• 3 Ji N, Li J, Wei Z, Kong F, Jin H, Chen X, Li Y, Deng Y. Effect of celastrol on growth inhibition of prostate cancer cells through the regulation of hERG channel in vitro . Biomed Res Int 2015; 2015: 308475
• 4 Nabekura T, Hiroi T, Kawasaki T, Uwai Y. Effects of natural nuclear factor-kappa B inhibitors on anticancer drug efflux transporter human P-glycoprotein. Biomed Pharmacother 2015; 70: 140-145
• 5 Shrivastava S, Jeengar MK, Reddy VS, Reddy GB, Naidu VG. Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3 K/Akt pathways. Exp Mol Pathol 2015; 98: 313-327
• 6 Chen Y, Yuan L, Zhou L, Zhang ZH, Cao W, Wu Q. Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine. Int J Nanomedicine 2012; 7: 4581-4591
• 7 Qi X, Qin J, Ma N, Chou X, Wu Z. Solid self-microemulsifying dispersible tablets of celastrol: formulation development, charaterization and bioavailability evaluation. Int J Pharm 2014; 472: 40-47
• 8 Zhang J, Li CY, Xu MJ, Wu T, Chu JH, Liu SJ, Ju WZ. Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats. J Ethnopharmacol 2012; 144: 195-200
• 9 Jin C, He X, Zhang F, He L, Chen J, Wang L, An L, Fan Y. Inhibitory mechanisms of celastrol on human liver cytochrome P450 1A2, 2C19, 2D6, 2E1 and 3A4. Xenobiotica 2015; 45: 571-577
• 10 Sun M, Tang Y, Ding T, Liu M, Wang X. Inhibitory effects of celastrol on rat liver cytochrome P450 1A2, 2C11, 2D6, 2E1 and 3A2 activity. Fitoterapia 2014; 92: 1-8
• 11 Yang H, Landis-Piwowar KR, Chen D, Milacic V, Dou QP. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment. Curr Protein Pept Sci 2008; 9: 227-239
• 12 Pinna GF, Fiorucci M, Reimund JM, Taquet N, Arondel Y, Muller CD. Celastrol inhibits pro-inflammatory cytokine secretion in Crohnʼs disease biopsies. Biochem Biophys Res Commun 2004; 322: 778-786
• 13 Sharma S, Mishra R, Walker BL, Deshmukh S, Zampino M, Patel J, Anamalai M, Simpson D, Singh IS, Kaushal S. Celastrol, an oral heat shock activator, ameliorates multiple animal disease models of cell death. Cell Stress Chaperones 2015; 20: 185-201
• 14 Wang S, Liu K, Wang X, He Q, Chen X. Toxic effects of celastrol on embryonic development of zebrafish (Danio rerio). Drug Chem Toxicol 2011; 34: 61-65
• 15 Lennernäs H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 2007; 37: 1015-1051
• 16 Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001; 46: 27-43
• 17 Hua WJ, Fang HJ, Hua WX. Transepithelial transport of rosuvastatin and effect of ursolic acid on its transport in Caco-2 monolayers. Eur J Drug Metab Pharmacokinet 2012; 37: 225-231
• 18 Artursson P. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci 1990; 79: 476-482
• 19 Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-885
• 20 Gutmann H, Fricker G, Torok M, Michael S, Beglinger C, Drewe J. Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake. Pharm Res 1999; 16: 402-407
• 21 Li N, Wang D, Sui Z, Qi X, Ji L, Wang X, Yang L. Development of an improved three-dimensional in vitro intestinal mucosa model for drug absorption evaluation. Tissue Eng Part C Methods 2013; 19: 708-719
• 22 Larregieu CA, Benet LZ. Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements. AAPS J 2013; 15: 483-497
• 23 Chen Y, Wang Y, Zhou J, Gao X, Qu D, Liu C. Study on the mechanism of intestinal absorption of epimedins A, B and C in the Caco-2 cell model. Molecules 2014; 19: 686-698
• 24 Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989; 96: 736-749
• 25 Joyce H, McCann A, Clynes M, Larkin A. Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. Expert Opin Drug Metab Toxicol 2015; 11: 795-809
• 26 Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-294
• 27 Lee WC, Peng CC, Chang CH, Huang SH, Chyau CC. Extraction of antioxidant components from Bidens pilosa flowers and their uptake by human intestinal Caco-2 cells. Molecules 2013; 18: 1582-1601
• 28 Nguyen MA, Staubach P, Wolffram S, Langguth P. Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans – Implications for the evaluation of transporter-mediated flavonoid-drug interactions. Eur J Pharm Sci 2014; 61: 54-60
• 29 Awortwe C, Fasinu PS, Rosenkranz B. Application of Caco-2 cell line in herb-drug interaction studies: current approaches and challenges. J Pharm Pharm Sci 2014; 17: 1-19
• 30 Manda VK, Avula B, Ali Z, Khan IA, Walker LA, Khan SI. Evaluation of in vitro absorption, distribution, metabolism, and excretion (ADME) properties of mitragynine, 7-hydroxymitragynine, and mitraphylline. Planta Med 2014; 80: 568-576
• 31 Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004; 36: 57-104
• 32 Amin ML. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 2013; 7: 27-34
• 33 Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets 2013; 13: 326-346
• 34 Yang JM, Ip SP, Xian Y, Zhao M, Lin ZX, Yeung JH, Chan RC, Lee SS, Che CT. Impact of the herbal medicine Sophora flavescens on the oral pharmacokinetics of indinavir in rats: the involvement of CYP3 A and P-glycoprotein. PLoS One 2012; 7: e31312
• 35 Zhang Y, Li J, Lei X, Zhang T, Liu G, Yang M, Liu M. Influence of verapamil on pharmacokinetics of triptolide in rats. Eur J Drug Metab Pharmacokinet advance online publication 9 April 2015
• 36 Li N, Tsao R, Sui Z, Ma J, Liu Z. Intestinal transport of pure diester-type alkaloids from an aconite extract across the Caco-2 cell monolayer model. Planta Med 2012; 78: 692-697
• 37 Zhang XA, Zhang S, Yin Q, Zhang J. Quercetin induces human colon cancer cells apoptosis by inhibiting the nuclear factor-kappa B pathway. Pharmacogn Mag 2015; 11: 404-409
• 38 Liang Y, Zhou Y, Zhang J, Liu Y, Guan T, Wang Y, Xing L, Rao T, Zhou L, Hao K, Xie L, Wang GJ. In vitro to in vivo evidence of the inhibitor characteristics of Schisandra lignans toward P-glycoprotein. Phytomedicine 2013; 20: 1030-1038
• 39 Sun JN, Shi YP, Chen J. Ultrasound-assisted ionic liquid dispersive liquid-liquid microextraction coupled with high performance liquid chromatography for sensitive determination of trace celastrol in urine. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 3429-3433
• 40 Manda VK, Avula B, Ali Z, Wong YH, Smillie TJ, Khan IA, Khan SI. Characterization of in vitro ADME properties of diosgenin and dioscin from Dioscorea villosa . Planta Med 2013; 79: 1421-1428